Skip to main content

Table 1 Summary of trials using CDK4/6 inhibitors in patients with metastatic hormone receptor-positive breast cancer

From: Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer

Agent

ET/Setting

Median PFS

HR

Trial

Palbociclib

Letrozole, 1st-line

24.8 vs 14.5 months

0.58

PALOMA-2

Palbociclib

Fulvestrant, 2nd-line

9.2 vs 3.8 months

0.42

PALOMA-3

Ribociclib

Letrozole, 1st-line

25.3 vs 16.0 months

0.56

MONALEESA-2

Abemaciclib

Fulvestrant, 2nd-line

16.4 vs 9.3 months

0.55

MONARCH-2

  1. ET endocrine therapy, PFS progression-free survival